DNA Direct and Iverson Genetics will Provide Personalized Patient Reports for Warfarin Dosing Test Results
News Jul 11, 2008
DNA Direct, Inc. and Iverson Genetic Diagnostics, Inc. have announced that the companies will collaborate to offer personalized reports for individuals receiving Iverson's molecular-based assay for testing sensitivity to warfarin, a commonly used anticoagulant.
DNA Direct will provide a customized, web-enabled tool for Iverson customers, allowing physicians who work with Iverson to offer their patients a personalized report that explains their test results in a patient-friendly, interactive format.
"We believe DNA Direct's clinical resources and genetic expertise will provide additional value to both physicians and patients through this web-based solution," said Ryan Phelan, founder and CEO of DNA Direct. "This collaboration will enable Iverson to offer a time-saving solution for physicians that also harnesses the Web's potential for enhancing patient care and maximizes the value of this diagnostic."
The web-enabled reports will be personalized to the patient's actual test results, explaining the implications for both general drug response and warfarin dosing. The reports will also explain how genes affect drug response, what factors impact warfarin dosing and what next steps may be most appropriate.
Patients will be able to download a copy of their lab report, as well as a clinical summary letter to be shared with their physicians. Patients may return to their report at a later date to determine how metabolism status may impact drug response for certain additional medications.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE